This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Teva to appeal EU antitrust sanction over MS drug

( October 31, 2024, 11:35 GMT | Official Statement) -- MLex Summary: Teva Pharmaceuticals has said it will appeal to the EU courts to overturn a European Commission fine related to its multiple-sclerosis drug Copaxone. The EU antitrust authority imposed a fine of 462.6 million euros for disparaging a rival drug and misusing the patent system. Teva said it "disagrees with the commission’s legal theories which are legally untested and … not supported by the facts." It said it would "vigorously defend its position on appeal and is well prepared financially to mount a defense."The statement follows:...

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Related Sections